The Rosen Law Firm today announced that a class action lawsuit has been filed on behalf of all purchasers of the common stock of Amarin Corporation plc (NASDAQ: AMRN) between July 9, 2009 through October 15, 2013 (the “Class Period”).
To join the Amarin class action, go to the website at
or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email
for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants issued materially false and misleading statements about Amarin’s true business and financial condition in violation of the federal securities laws. Specifically, the complaint alleges that: (i) defendants misrepresented the prospects for U.S. Food and Drug Administration (“FDA”) approval of Amarin’s lead product Vascepa, which supposedly reduces triglycerides levels in adult patients; and (ii) defendants failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data indicating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk. The complaint alleges that when this adverse information was disclosed, it caused the price of Amarin stock to drop, damaging investors.
A class action lawsuit has already been filed on behalf of Amarin investors. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2014. If you wish to join the litigation or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at
The Rosen Law Firm focuses on prosecuting securities class action litigation and actions involving financial fraud. The Rosen Law Firm represents investors throughout the globe concentrating its practice in securities class actions.